Dr. Goodenowe has been invited to present alongside other leaders in anti-aging medicine at the A4M Brain Health Summit June 26-27. He shares his expertise in two sessions: Good Oxygen and Bad Oxygen – Mitochondria, Oxidative Stress and Neurodegeneration and Good Fat and Bad Fat – Plasmalogens, Membranes, and Brain Function. From the program’s website: “This cutting-edge meeting will feature the field’s most esteemed clinicians, researchers, and educators presenting the latest clinical knowledge through a practical format that you can integrate into your clinical care approach by Monday morning. “ View more information about the event, including the program agenda, and register for the

All healthcare professionals part of the ProdromeScan Certification Course are invited to Dr. Goodenowe’s Physician Roundtable Group. This group meets regularly through video conference to discuss case studies from the doctors using the ProdromeScan blood test with their patients, with a particular focus on diseases of interest. The conference videos are uploaded to the Group and available to all Group Members.  The first Roundtable Meeting is Saturday, July 10th at 11:00 AM PT. Dr. Goodenowe is the presenting host for the first meeting. Dr. Goodenowe will review the results of the Plasmalogen Clinical Trial with Dr. Sheldon Jordan. These results are being presented at the AAIC Conference on July 26th. Those trial results will not be available

The anticipated release date for Dr. Dayan Goodenowe’s new book is June 25, 2021. Pre-orders are now available for Breaking Alzheimer’s: A 15 Year Crusade to Expose the Cause and Deliver the Cure. Pre-order here. Breaking Alzheimer’s is Dr. Dayan Goodenowe’s story of personal and scientific perseverance. The biochemical mechanisms of neurological disease is his area of expertise and was his area of expertise for 15 years before he serendipitously discovered that low plasmalogen levels were causing Alzheimer’s. Dr. Goodenowe had never heard of plasmalogens and he had never been taught about them. There are now 15 years of supportive validation of

Dr. Goodenowe has over 30 years of diverse scientific research experience and has explored topics ranging from software, to mechanics, to theoretical physics, to neuroscience. From this vast knowledge, he creates regular presentations and videos exploring many topics of great interest to him and shares what he has learned. Each seminar has a written article and a video. These seminar videos contain relevant literature excerpts and detailed explanations. Seminars include Longevity and Immortality (Series A), Blood Tests and Biomarkers (Series B), and Supplements (Series C), with more to come. Register here to access the FREE seminars with full presentations and videos.

Dr. Dayan Goodenowe is passionate about sharing his knowledge of the biochemistry of health and disease. He has launched his ProdromeScan Certification Course to share this knowledge with you!   The ProdromeScan test is a multi-system blood test specifically designed to assist advanced functional medicine doctors in achieving optimal biochemical health for themselves and their patients. It does so by measuring hundreds of biomarkers and organizing this information into specific biosystems known to be associated with advanced health and longevity. The course is self-paced with 10 modules: Module 1 – Introduction to Biochemical Prodromes of Health and Disease Module 2 –

Ben Greenfield is a leader in health and fitness coaching and has been named the one of the world’s top 100 most influential people in health and fitness. He completed his follow up ProdromeScan blood test after taking Dr. Goodenowe’s scientifically designed ProdromeNeuro plasmalogen supplement for three months. Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, reviewed Ben Greenfield’s before and after blood test results in a video you can watch on his website here or on his YouTube channel here. Ben Greenfield says, “I know it’s a lot of detail, but the information that ProdromeScan collects is like a gold mine for understanding

Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, joined host Daniel Eisenman on his podcast Breaking Normal to discuss plasmalogens, the ProdromeScan blood test, and the science and research behind the Prodrome products. It was a pleasure to speak to Daniel and we thank him for the invitation and his time! Listen to the podcast here.

Plasmalogen Deficiency and its Role in Neurodegenerative Diseases and Accelerated Mortality: What Every Doctor Must Know Please join host Dr. Mitchell Fleisher and presenter Prodrome Sciences Founder and CEO Dr. Dayan Goodenowe, for a live webinar on Saturday, February 20th at 10:00 am PST. Learn: What plasmalogens are and why they are essential for optimal health and longevity Plasmalogens and their association with aging and neurodegenerative diseases How to replenish and build plasmalogen reserves Dr. Goodenowe will present the preliminary results of the clinical trial in Alzheimer’s Disease following his presentation. If you are already a registered practitioner with Prodrome,

Dr. Dayan Goodenowe had the pleasure of introducing the power of the ProdromeScan blood test to Ben Greenfield. You can read his article about his experience and watch a video of Dr. Goodenowe reviewing his results here. Ben is a leader in health and fitness coaching and has been named the one of the world’s top 100 most influential people in health and fitness.

Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, was invited to discuss plasmalogens on the Dr. Gundry Podcast. It was a pleasure to speak with Dr. Gundry to explain the extensive research and clinical trial evidence behind plasmalogens and dementia as well as the importance of supplementing with plasmalogens for overall health and vitality. Access the podcast here: Apple episode:https://podcasts.apple.com/us/podcast/the-dr-gundry-podcast/id1434371530#episodeGuid=c74741c9-4fcd-4a44-93e3-d52babaa3ed5 Show notes:https://drgundry.com/dayan-goodenowe/ Youtube episode:https://www.youtube.com/watch?v=0yxDSalBOY8

Dr. Goodenowe presented recent clinical research results at a symposium at the 67th Annual Meeting of Japanese Society of Laboratory Medicine on November 22. He presented results from a study on 1,128 persons including 374 colorectal cancer subjects and 187 pancreatic cancer subjects as well as a 6-month study on plasmalogen supplementation with ProdromeNeuro in 20 neurological patients. Blood samples were analyzed using the ProdromeScan blood test technology. The ProdromeScan blood test results confirmed low GTA and low plasmalogen levels in both cancers and the neurological disease subjects, as previously reported by Dr. Goodenowe. ProdromeNeuro plasmalogen supplementation elevated target blood

Another important paper was published by independent researchers confirming Dr. Goodenowe’s (Founder and CEO, Prodrome Sciences) original discovery and hypothesis that plasmalogen deficiency is the key underlying causative factor in Alzheimer’s. In this new paper, researchers did a comprehensive comparison of blood biomarkers of Alzheimer’s in two large clinical trials – one from the USA and one from Australia. The results unambiguously reveal that not only are all classes of plasmalogen phospholipids deficient in persons with Alzheimer’s, but that alkyl-acyl glycerols (the biochemical precursors of plasmalogens) are the most depleted. Prodrome Sciences’ alkyl-acyl glycerol plasmalogen supplements are the only proven bioavailable plasmalogen

Prodrome Sciences and Kyoto Prefectural University presented the results from their collaboration on breast cancer biochemistry at the 28th Annual Meeting of The Japanese Breast Cancer Society. The collaboration investigated the biochemical status of women diagnosed with breast cancer before and after surgery and treatment using Prodrome’s ProdromeScan blood testing technology. Two separate clinical populations involving 300 persons were used to validate the findings. The first population was a cross-sectional study of women prior to treatment and the second study was a longitudinal study that enrolled women at diagnosis and followed them through their treatment protocols. Consistent with Dr. Goodenowe’s previous

Dr. Dayan Goodenowe, Prodrome’s Founder and CEO, is presenting at this year’s RAAD Festival alongside leaders in longevity science. His presentation is on the Biochemical Basis of Longevity: How to measure and optimize human biochemistry for maximum lifespan. We look forward to the event this weekend! View the event information here.

Several recently published peer-reviewed research articles from independent and prestigious research institutions involving large, well-characterized populations of persons suffering from Alzheimer’s disease and related dementias have unanimously concluded that low blood plasmalogen levels are linked to dementia: as originally discovered and described by Dr. Dayan Goodenowe, Prodrome Sciences’ Founder and CEO, in his landmark 2007 paper. As a result, there is considerable interest in how to increase blood plasmalogen levels.   Dr. Chris Meletis recently published a review in Integrative Medicine in which he thoroughly investigated both the link between plasmalogens and Alzheimer’s disease and the various technologies available to elevate blood plasmalogens. His

A clinical trial is underway using the ProdromeNeuro plasmalogen oil supplement in subjects with a confirmed diagnosis of mild to moderate dementia. The trial is taking place at the Neurological Associates of West Los Angeles clinic in Santa Monica, California, run by Dr. Sheldon Jordan, a pioneer in advanced brain imaging and cutting edge neurological interventions. Click here to read his extensive CV. All participants will be evaluated at baseline and at the end of each month for changes in blood plasmalogen levels, cognition, mobility, and quality of life metrics. For further details about the clinical trial design, please visit the

Prodrome Sciences launches a new supplement, ProdromeGTA. The history and science behind ProdromeGTA is very interesting. In 1999, Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences, invented a revolutionary technology called Non-Targeted Complex Sample Analysis. Dr. Goodenowe’s invention enabled, for the first time, thousands of biochemicals in a biological sample to be simultaneously measured. When Dr. Goodenowe applied his patented technology to the study of various cancers in the mid 2000s, he discovered that there was an entire new class of biochemicals in human blood that doctors and scientists never even knew existed and that these naturally occurring biochemicals,

New research published from a study of 1,112 individuals in Australia further confirms that plasmalogen molecules are low in persons with Alzheimer’s disease. The authors found that low plasmalogens are associated with all risk factors of Alzheimer’s disease and with the disease itself. This independent, peer-reviewed research supports Dr. Goodenowe’s original hypothesis from his landmark 2007 paper titled “Peripheral Ethanolamine Plasmalogen Deficiency – A Logical Causative Factor in Alzheimer’s Disease and Dementia”. Prodrome Sciences offers blood testing to measure plasmalogen levels and natural plasmalogen supplements, ProdromeNeuro and ProdromeGlia, for the safe and effective restoration of these critical molecules.

Dr. Goodenowe’s landmark research paper titled “Peripheral Ethanolamine Plasmalogen Deficiency – A Logical Causative Factor in Alzheimer’s Disease and Dementia” was originally published in 2007. Since then Dr. Goodenowe has continued to collaborate with leading researchers from around the world to further advance our knowledge on how plasmalogen molecules affect other biomarkers and risk factors of Alzheimer’s disease. Dr. Goodenowe and colleagues from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) published a major paper involving 1659 subjects today that confirmed Dr. Goodenowe’s previous findings linking low blood plasmalogens and cognitive impairment and further showed that persons with low blood plasmalogens have higher levels

Thank you Dr. Adam Rinde for having Dr. Dayan Goodenowe on your podcast to discuss the strong science behind Prodrome Sciences’ plasmalogen products. Click here to listen and click here to read more from Dr. Rinde’s website. 

It was a pleasure to speak to Dr. Jannine Krause on the Health Fix Podcast about Prodrome Sciences’ plasmalogen oil supplements, ProdromeScan blood test, and research. Click here to listen to the podcast.

Prodrome Sciences offers another important plasmalogen oil product through valued healthcare professionals to help their patients achieve optimal health! ProdromeGlia is a biochemical plasmalogen supplement designed to restore, maintain, and optimize glia membranes and to create a biochemical reserve of critical membrane building material for glia membrane repair when needed. Glia are the cells in your brain and spinal cord that surround, support, protect, and insulate neurons, commonly referred to as white matter. Inflammation-mediated diseases like autism and multiple sclerosis as well as cerebrovascular and cardiovascular disease attack and degrade white matter. ProdromeGlia is specifically designed to provide the omega-9

Dr. Goodenowe talks about the genetics and metabolomics of Alzheimer’s the on ApoE4.info, Inc. podcast. ApoE4.info, Inc. is a non-profit group dedicated to understanding the APOE-ε4 allele and how it affects health. With personal genetic testing becoming so common now, many people are learning that they are at increased risk for Alzheimer’s disease and dementia as E4 genetic carriers. Dr. Goodenowe was invited to speak to Julie Gregory, President of ApoE4.info, to share his expertise on Alzheimer’s disease, including APOE-ε4, and plasmalogen molecules. They spoke about the genetics and metabolomics of persons with the Apoe e4 genotype and why apoe e4

Research on asthma, lung function, and plasmalogens demonstrates how important plasmalogens are for many areas of health. Levels decrease with age as the body can no longer make as much as it needs and the body uses up plasmalogens as anti-inflammatory and antioxidant molecules. ProdromeNeuro Plasmalogen Oil, is scientifically designed by Dr. Goodenowe to increase levels and maintain at a healthy and protective level. The body needs plasmalogens for optimal nerve cell function and they make up as much as 20% of the brain. Plasmalogens are also found in high concentrations in the heart, lungs, eyes, and kidneys.  The latest research

Dr. Goodenowe applies his technology to move beyond the treatment and prevention of diseases. Why be satisfied with the mere prevention of a negative outcome, like disease, when our technology and products can help people attain a positive outcome of optimal health, vitality, and longevity? Dr. Goodenowe had a chance to speak with Longevity Technology about his technology, products, and vision of how longevity science will ultimately create a new model of healthcare. Read the article here.

Prodrome Sciences shares the exciting research behind plasmalogen molecules in a featured blog post on Dr. Kara Fitzgerald’s website. Read the article here to learn more about the role of plasmalogens in health and why you do not want to risk having low levels of these critical molecules.

Thank you to People Unlimited for inviting Dr. Dayan Goodenowe to speak at the January Super Longevity Weekend in Scottsdale, Arizona. It was a pleasure to share Prodrome’s vision of optimizing biochemical health in order to achieve lasting health, vitality, and longevity. 

ProdromeNeuro Plasmalogen Oil is a pure, natural, plasmalogen precursor designed to elevate specific plasmalogens in the blood. Low levels of plasmalogens are associated with an increased risk of Alzheimer’s disease and early death. Six adults aged 23-56 took a single oral 100mg/kg dose (10-times the recommended daily dose) of Prodrome-Neuro Plasmalogen Oil and then plasmalogen levels were measured in blood samples at timed intervals. The target plasmalogen level significantly increased in every subject at 24 hours (p<0.001). The average 24-hour blood level was 180% of starting levels. As designed, non-targeted plasmalogens were not elevated. No adverse reactions were observed.  A daily

Collaborators at the Buck Institute and OpenOme presented exciting data on Prodrome-Neuro Plasmalogen Oil in flies. Promising early results of Prodrome-Neuro Plasmalogen Oil in flies was presented at the Bay Area Aging Meeting (BAAM) at Stanford University, California on December 5. The experiments were conducted by researchers from OpenOme Inc. and the Buck Institute for Aging Research. Flies have a short life span and respond less to light as they age. Flies supplemented with Prodrome-Neuro Plasmalogen Oil had significantly improved eyesight and response to light. The results are very exciting and we look forward to continued research with Prodrome’s plasmalogen

Recent research from Laval University demonstrates the critical role of plasmalogens in Parkinson’s disease. The research revealed that treatment of plasmalogens in a mouse model of Parkinson’s disease had anti-inflammatory effects in the gut and neuroprotective properties. There is increased interest in the research community about the role of the gut in Parkinson’s disease and this recent publication highlights the potential role of plasmalogens in gut health. The research was conducted using PPI-1011, a plasmalogen precursor drug that was invented by Dr. Dayan Goodenowe, Founder and CEO of Prodrome Sciences. PPI-1011 is no longer being developed by Dr. Goodenowe since he

Dr. Goodenowe was invited to present to over 500 gastroenterologists at the 35th Annual Educational Seminar of the Japan Gastroenterology Study. Dr. Goodenowe presented information about his blood test, Prodrome-PAC, for the identification of persons with high pancreatic cancer risk. Prodrome Sciences and NK Medico (Japan) are pleased with and appreciate the growing support for Prodrome-PAC throughout Japan. 

Dr. Goodenowe, Founder of Prodrome Sciences, presented his research on plasmalogens and neurodegeneration and the strong clinical data supporting plasmalogen supplementation as a strategy to prevent and treat dementia and to increase longevity. He presented Prodrome Sciences’ Prodrome-Neuro Plasmalogen Oil dietary supplement product, which will be studied in Alzheimer’s patients with support from a grant from the Alzheimer’s Association.

Plasmalogen molecules, critical lipids required for brain and nerve function, have been researched extensively since Dr. Goodenowe (Founder and CEO, Prodrome Sciences) first published his hypothesis about the role of plasmalogens in dementia in 2007. The Alzheimer’s Association has even funded a clinical trial for Prodrome Sciences to make a natural plasmalogen supplement for study in Alzheimer’s patients. Prodrome Sciences’ newest paper on the topic is a major achievement that outlines the strong evidence that plasmalogen molecules play a key role in the cause of Alzhiemer’s.  Click here to view the paper online.

Dr. Goodenowe’s latest peer-reviewed published research shows that a person’s levels of plasmalogens, a critical lipid molecule required for brain and nerve function, is a better indicator of risk of Alzheimer’s disease than the established genetic risk factor APOE e4. This research further emphasizes the need for a plasmalogen blood test to assess risk of Alzheimer’s disease as well as a safe and natural plasmalogen supplement to increase levels of plasmalogens. Click here to view the publication.

Based upon Dr. Goodenowe’s research linking high plasmalogen levels with a low risk of Alzheimer’s disease, the Alzheimer’s Association (Chicago, USA) is funding a clinical trial to investigate the effects of Prodrome Sciences’ novel plasmalogen precursor supplement in persons diagnosed with mild Alzheimer’s disease. Plasmalogens are a type of lipid (fat) molecule that are an important part of cells and help nerve cells communicate. There are no good sources of plasmalogens through the diet and levels decline dramatically after age 50. The Alzheimer’s disease clinical biomarker trial will be led by Dr. Mitchel Kling, Associate Professor of Psychiatry at the Hospital

Dr. Goodenowe’s latest peer-reviewed publication is on research results from a community trial of 1,205 persons (average age = 84) that showed that elderly persons with high blood plasmalogens had a dramatically lower rate of dementia (6%) versus persons with low blood plasmalogens (31%). In addition, it was observed that high blood plasmalogens was also associated with a lower risk of Alzheimer’s disease in persons with a high genetic risk of the disease. This is a critical observation because it shows that a person’s biochemical status affects their genetic risk for a disease, which means that it may be possible

Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention are analyzing over 3,000 samples of Japanese persons with confirmed diagnoses of colorectal or pancreatic cancer and persons of average risk. The goal of the research collaboration is to determine if Prodrome Sciences’ new ProdromeScan technology can improve the accuracy of Prodrome Sciences’ current Prodrome-CRC blood test for colorectal cancer and Prodrome-PAC blood test for pancreatic cancer, which simultaneously measure 20 different GTA (gastrointestinal tract acid) species. Prodrome Sciences’ new ProdromeScan technology simultaneously measures not only GTAs,

Prodrome Sciences Inc.; Chiba University Hospital, Division of Clinical Mass Spectrometry; Chiba Cancer Center; and Chiba Foundation for Health Promotion & Disease Prevention have completed year two of a three-year collaboration comparing the clinical mass spectrometric analysis of serum GTAs (gastrointestinal tract acids) and FIT (fecal immunohistochemical) tests for identifying persons with increased risk of colorectal cancer. As part of the collaboration, the Chiba Health Foundation collects blood and fecal samples from individuals undergoing colorectal cancer screening. Prodrome Sciences measures serum GTA levels using its high-throughput, high-resolution, accurate-mass technology and the Chiba Health Foundation performs FIT analyses. Over 3,000 participants

Plasmalogens are critical molecules needed for optimal health and nerve and brain function. The role of plasmalogens in neurodegenerative diseases such as Alzheimer’s is well established. Dr. Goodenowe’s newest paper published with collaborators at the National Center of Neurology and Psychiatry in Japan highlights just how important plasmalogens are to health. Patients with bipolar disorder had significantly lower levels of plasmalogens. Click here for the publication.

Prodrome Sciences and Kyoto Prefectural University of Medicine (Department of Epidemiology for Community Health and Medicine) are proud to announce they have begun a collaborative biomarker research study to investigate longitudinal biomarker changes associated with dietary lifestyle diseases, dementia, cancer, and locomotive syndrome using Prodrome Sciences’ patented comprehensive metabolomics technology and blood samples collected as part of the Japan Multi-Institutional Collaborative Cohort Study (J-MICC) from this year. Prodrome Sciences will perform comprehensive metabolomics analyses on over 5,000 blood samples collected from 2012 through 2019. Prodrome Sciences and Kyoto will work together to investigate the relationship between biochemical changes associated with

Dr. Dayan Goodenowe was recently interviewed by PM360 Magazine. Click here to read the article.

The Scientific American published an article on July 25, 2018, titled “A Gut – and Liver – Check to Get a Bead on Alzheimer’s” which reviews research results presented by Dr. Mitchel A. Kling, MD, on July 24 at the Alzheimer’s Association International Conference (AAIC) 2018. The July 24 AAIC presentation session titled “Gut-Liver-Brain Axis in Alzheimer’s Disease” included a presentation of recent research results where Dr. Dayan Goodenowe is an author. Dr. Dayan Goodenowe published his original findings linking plasmalogens with Alzheimer’s disease in a 2007 peer-reviewed research publication titled “Peripheral Ethanolamine Plasmalogen Deficiency: A Logical Causal Factor in Alzheimer’s Disease and Dementia”.

On July 24, the Alzheimer’s Association International Conference (AAIC) held a session titled “Gut-Liver-Brain Axis in Alzheimer’s Disease” where researchers from the multi-institutional Alzheimer’s Disease Metabolomics Consortium presented research results confirming Dr. Goodenowe’s original research findings linking low blood plasmalogen levels with increased risk of dementia. Dr. Goodenowe published his original findings in a 2007 peer-reviewed research publication titled “Peripheral Ethanolamine Plasmalogen Deficiency: A Logical Causal Factor in Alzheimer’s Disease and Dementia”. In addition to these original discoveries, Dr. Goodenowe subsequently developed and tested simplified blood plasmalogen indices in longitudinal patient cohorts and post-mortem pathology studies. These studies link blood plasmalogen deficiencies with

Dr. Dayan Goodenowe, Prodrome Sciences’ Founder and CEO, will present the validation study results of Prodrome Sciences’ new multi-analyte, high-resolution/accurate-mass technology for the quantification of over 1000 acidic lipid species in human serum at the 43rd Annual Meeting of the Japanese Society for Biomedical Mass Spectrometry on September 6, 2018, in Sapporo, Japan. Diseases such as colorectal cancer, pancreatic cancer, ovarian cancer, multiple sclerosis, Parkinson’s disease, and dementia are associated with abnormal blood levels of acidic lipids such as fatty acids (EPA, DHA), ultra-long chain fatty acids (GTA-446, PC-594), plasmalogens, phosphatidylethanolamines, and phosphatidylserines. Prodrome Sciences has developed and validated a

Dr. Dayan Goodenowe will present the results of Prodrome Sciences’ Japanese population distribution study of colorectal cancer associated gastrointestinal tract acids (GTAs) at the 59th Annual Scientific Meeting of Japan Society of Ningen Dock International on August 30, 2018, in Niigata, Japan. Using Dr. Goodenowe’s patented high-resolution/accurate-mass technology, it was previously discovered that blood levels of certain ultra-long-chain fatty acids, called GTAs, are low in persons diagnosed with colorectal cancer. Over 90% of persons with colorectal cancer have low levels of GTAs in their blood. Low levels of GTAs in blood is a validated risk factor for colorectal cancer. When

Prodrome Sciences Inc. and NK Medico are proud to announce they have agreed to an exclusive distribution agreement for the sale of Prodrome Sciences’ multi-analyte risk assessment tests based on Dr. Dayan Goodenowe’s ProdromeScan blood testing technology in Japan. Prodrome Sciences has developed improved blood testing technology for identifying persons with a high risk of colorectal cancer or pancreatic cancer. The new tests, Prodrome-CRC and Prodrome-PAC, use Prodrome Sciences’ patented high-resolution/accurate-mass technology to simultaneously quantitate multiple biomarkers associated with an increased risk of colorectal or pancreatic cancer. The new tests overcome several technical deficiencies associated with the older, low-resolution, single-analyte

Prodrome Sciences Inc. and the National Center of Neurology and Psychiatry (NCNP) in Japan are proud to announce they have initiated an integrated multi-disease research study to discover and validate blood and cerebral spinal fluid biomarkers for psychiatric and neurological diseases using Prodrome Sciences’ patented comprehensive metabolomics technology and biospecimens from NCNP’s neurological disease BioBank and database. Prodrome Sciences will analyze over 1000 biospecimens from multiple psychiatric and neurological diseases such as schizophrenia, bipolar disorder, depression, and dementia. The goals of the research collaboration are to advance the biochemical understanding of psychiatric and neurological diseases to improve patient diagnosis and

Prodrome Sciences is proud to announce the commercial launch of Prodrome-CRC – the high-resolution/accurate mass blood test for assessing colorectal cancer risk. Prodrome-CRC is a simple blood test that requires no advance preparations and no fecal handling. The multi-analyte test accurately determines if a person has a Gastrointestinal Tract Acid (GTA) deficiency, a validated risk factor for colorectal cancer. A simple, accessible blood test such as Prodrome-CRC has the potential to increase colorectal cancer testing compliance leading to earlier disease detection when the cancer is easier to treat. The association between low blood levels of GTAs and an increased risk

Prodrome Sciences is proud to announce the commercial launch of Prodrome-PAC – the high-resolution/accurate mass blood test for assessing pancreatic cancer risk. Prodrome-PAC is a simple blood test that requires no advance preparation. The multi-analyte test accurately determines if a person has a pancreatic cancer specific biomarker deficiency. By knowing pancreatic cancer risk, a person can be monitored closely for the disease in order to detect the cancer at an earlier stage when it is easier to treat. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Over 85% of persons diagnosed with pancreatic cancer

Dr. Goodenowe has been invited to give a scientific presentation on October 26, 2017, at the Campus Alberta Neuroscience Symposium, Neurotechnology for Discovery and Translation. The title of Dr. Goodenowe’s talk is, “Bipolar Disorder: Biology, serum biomarkers, and opportunities to improve patient management”. Dr. Goodenowe’s talk will provide the audience with an overview on the biochemical dysfunctions present in bipolar disorder, the potential for serum biomarkers that can identify and differentiate bipolar disorder from major depressive disorder and schizophrenia and how biomarkers could be used to improve patient management through better and more efficient diagnosis.

Dr. Goodenowe has been invited by the Prince Edward Island BioAlliance to deliver a public lecture on the current status of Alzheimer’s disease research at Holland College in Charlottetown, PEI, Canada on July 9, 2017. The title of Dr. Goodenowe’s lecture is, “The Search for the Cause and the Cure for Alzheimer’s Disease and Related Dementias: Genes, Proteins, Metabolites, What Does it All Mean?” Although scientific in nature, the lecture is intended for a general public audience. Everyone is welcome.